
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/869094/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24.	1.9	1
2	Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase lb study. Investigational New Drugs, 2022, 40, 290-299.	2.6	3
3	Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i> / <i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study. Cancer Discovery, 2022, 12, 402-415.	9.4	119
4	Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer, 2022, 128, 509-518.	4.1	10
5	Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 2022, 28, 677-688.	7.0	119
6	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	3.3	3
7	Natural Language Processing–Assisted Literature Retrieval and Analysis for Combination Therapy in Cancer. JCO Clinical Cancer Informatics, 2022, 6, e2100109.	2.1	4
8	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	1.4	1
9	Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precision Oncology, 2022, 6, e2100267.	3.0	28
10	Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. Journal of Immunotherapy and Precision Oncology, 2022, 5, 10-12.	1.4	0
11	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clinical Cancer Research, 2022, 28, 1540-1548.	7.0	21
12	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i> -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precision Oncology, 2022, 6, e2100197.	3.0	10
13	Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clinical Cancer Research, 2022, 28, 2020-2029.	7.0	18
14	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery, 2022, 12, 654-669.	9.4	34
15	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports, 2022, 40, 100974.	0.6	5
16	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
17	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , .	7.0	3
18	A functional genomic approach to actionable gene fusions for precision oncology. Science Advances, 2022, 8, eabm2382.	10.3	9

#	Article	IF	CITATIONS
19	Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE. Clinical Cancer Research, 2022, 28, 2118-2130.	7.0	3
20	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
21	Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Network Open, 2022, 5, e2213070.	5.9	21
22	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision Oncology, 2022, , .	3.0	15
23	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	5.5	90
24	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discovery, 2021, 11, 80-91.	9.4	148
25	Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, The, 2021, 397, 1010-1022.	13.7	196
26	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	3.4	7
27	Doseâ€escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> â€mutated advanced cancers. Cancer, 2021, 127, 391-402.	4.1	6
28	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ^'positive Metastatic Breast Cancer or Other Solid Tumors. Clinical Cancer Research, 2021, 27, 1247-1255.	7.0	5
29	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
30	Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study Journal of Clinical Oncology, 2021, 39, 299-299.	1.6	40
31	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. Clinical Cancer Research, 2021, 27, 2996-3004.	7.0	23
32	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist, 2021, 26, 558-e1098.	3.7	18
33	Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature, 2021, 592, 302-308.	27.8	145
34	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research, 2021, 23, 29.	5.0	31
35	Next generation sequencing for biliary tract cancers. Expert Review of Gastroenterology and Hepatology, 2021, 15, 471-474.	3.0	9
36	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clinical Cancer Research, 2021, 27, 3050-3060.	7.0	24

#	Article	IF	CITATIONS
37	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3243-3252.	7.0	14
38	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multiâ€arm phase lb study. Investigational New Drugs, 2021, 39, 1357-1365.	2.6	5
39	Precision Medicine in Oncology—Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. JAMA Oncology, 2021, 7, 507.	7.1	13
40	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist, 2021, 26, 588-596.	3.7	42
41	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. OncoTargets and Therapy, 2021, Volume 14, 3037-3049.	2.0	2
42	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. Journal of Immunotherapy and Precision Oncology, 2021, 4, 45-52.	1.4	5
43	Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene, 2021, 40, 4425-4439.	5.9	11
44	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Research, 2021, 81, CT010-CT010.	0.9	28
45	Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, 28, 5477-5485.	1.5	3
46	A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2021, 27, 4994-5003.	7.0	24
47	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74
48	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A PhaseÂll Trial. Advances in Therapy, 2021, 38, 4581-4591.	2.9	7
49	O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*. Annals of Oncology, 2021, 32, S285.	1.2	5
50	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
51	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.7	178
52	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Targeted Oncology, 2021, 16, 569-589.	3.6	10
53	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 5572-5581.	0.9	75
54	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical Cancer Research, 2021, 27, 1681-1694.	7.0	33

#	Article	IF	CITATIONS
55	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precision Oncology, 2021, 5, 133-144.	3.0	22
56	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study Journal of Clinical Oncology, 2021, 39, 164-164.	1.6	21
57	ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, , 1.	1.5	0
58	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	27.0	363
59	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. Npj Precision Oncology, 2021, 5, 99.	5.4	2
60	Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Experimental Hematology and Oncology, 2021, 10, 59.	5.0	4
61	Phase II, 2â€stage, 2â€arm, PIK3CA mutation stratified trial of MKâ€2206 in recurrent endometrial cancer. International Journal of Cancer, 2020, 147, 413-422.	5.1	31
62	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587.	7.0	16
63	Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1808-1812.	4.4	15
64	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020, 5, e001073.	4.5	1
65	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology, 2020, 159, 150-156.	1.4	43
66	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open, 2020, 5, e000799.	4.5	45
67	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	27.0	1,049
68	Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clinical Cancer Research, 2020, 26, 5830-5842.	7.0	17
69	Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort. International Journal of Medical Informatics, 2020, 143, 104261.	3.3	3
70	COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission. Annals of Surgical Oncology, 2020, 27, 2591-2599.	1.5	12
71	46. ClinGen somatic cancer working group: Enhancing standardized interpretation of cancer genetic data for clinical use. Cancer Genetics, 2020, 244, 17-18.	0.4	0
72	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623.	1.1	43

#	Article	IF	CITATIONS
73	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	7.0	50
74	Prospecting whole cancer genomes. Nature Cancer, 2020, 1, 273-275.	13.2	0
75	Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin–Stained Sections of Core-Needle Biopsy Specimens. JAMA Network Open, 2020, 3, e200476.	5.9	19
76	Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	9.4	93
77	State-of-the-Art Strategies for Targeting <i>RET</i> -Dependent Cancers. Journal of Clinical Oncology, 2020, 38, 1209-1221.	1.6	172
78	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	9.4	83
79	Characteristics and Outcome of <i>AKT1</i> E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discovery, 2020, 10, 526-535.	9.4	36
80	Antibody-Drug Conjugates: Patient and Treatment Selection. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 105-114.	3.8	12
81	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Scientific Reports, 2020, 10, 22087.	3.3	21
82	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. Annals of Surgery Open, 2020, 1, e008.	1.4	18
83	Targeting PI3KÎ ² alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget, 2020, 11, 969-981.	1.8	17
84	Incorporating Precision Medicine into Phase I Clinical Trials. , 2020, , 221-231.		0
85	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist, 2019, 24, 219-228.	3.7	30
86	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
87	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clinical Cancer Research, 2019, 25, 6107-6118.	7.0	54
88	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research, 2019, 21, 78.	5.0	141
89	HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology, 2019, 92, 32-38.	2.0	12
90	Targeting AKT for cancer therapy. Expert Opinion on Investigational Drugs, 2019, 28, 977-988.	4.1	150

#	Article	IF	CITATIONS
91	Exposure to antiâ€PDâ€1 causes functional differences in tumorâ€infiltrating lymphocytes in rare solid tumors. European Journal of Immunology, 2019, 49, 2245-2251.	2.9	4
92	Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
93	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precision Oncology, 2019, 3, 1-12.	3.0	20
94	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. European Journal of Cancer, 2019, 120, 54-64.	2.8	18
95	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Targeted Oncology, 2019, 14, 591-601.	3.6	43
96	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	16.8	145
97	Rapamycinâ€ ⁻ â^'â€ ⁻ mTORâ€ ⁻ +â€ ⁻ BRAFâ€ ⁻ =â€ ⁻ ? Using relational similarity to find therapeutically relevant drug-gen relationships in unstructured text. Journal of Biomedical Informatics, 2019, 90, 103094.	1e 4.3	1
98	Oncogenic IncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 2019, 20, 835-851.	14.5	277
99	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	4.1	26
100	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	10.7	362
101	Clinical and molecular characterization of earlyâ€onset colorectal cancer. Cancer, 2019, 125, 2002-2010.	4.1	212
102	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. JCO Precision Oncology, 2019, 3, 1-14.	3.0	12
103	Integrated transcriptomic–genomic tool Texomer profiles cancer tissues. Nature Methods, 2019, 16, 401-404.	19.0	7
104	Prospective Clinical Sequencing of Adult Glioma. Molecular Cancer Therapeutics, 2019, 18, 991-1000.	4.1	15
105	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	7.0	42
106	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations. Clinical Cancer Research, 2019, 25, 2699-2707.	7.0	98
107	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10.	3.0	6
108	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surgery and Nutrition, 2019, 8, 604-614.	1.5	34

#	Article	IF	CITATIONS
109	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research, 2019, 25, 7381-7387.	7.0	13
110	Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. JCO Clinical Cancer Informatics, 2019, 3, 1-12.	2.1	15
111	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. JCO Precision Oncology, 2019, 3, 1-11.	3.0	9
112	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	3.0	46
113	Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine. Diseases of the Colon and Rectum, 2019, 62, 429-437.	1.3	21
114	OCTANE: Oncology Clinical Trial Annotation Engine. JCO Clinical Cancer Informatics, 2019, 3, 1-11.	2.1	26
115	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. JAMA Oncology, 2019, 5, 45.	7.1	16
116	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clinical Cancer Research, 2019, 25, 2033-2041.	7.0	224
117	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF â€mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472.	4.1	10
118	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas Journal of Clinical Oncology, 2019, 37, 2507-2507.	1.6	113
119	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors Journal of Clinical Oncology, 2019, 37, 3014-3014.	1.6	50
120	FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells. Oncotarget, 2019, 10, 30-44.	1.8	13
121	TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget, 2019, 10, 5011-5019.	1.8	3
122	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. Oncotarget, 2019, 10, 6526-6535.	1.8	15
123	Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Annals of Translational Medicine, 2019, 7, 179-179.	1.7	56
124	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	4.3	13
125	Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing. Journal of Immunotherapy and Precision Oncology, 2019, 2, 137-143.	1.4	16
126	Next-generation sequencing for the general cancer patient. Clinical Advances in Hematology and Oncology, 2019, 17, 447-454.	0.3	6

#	Article	IF	CITATIONS
127	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer, 2018, 118, 763-769.	6.4	28
128	Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036
129	Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291.	27.6	762
130	Personalized cancer therapy—leveraging a knowledge base for clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a001578.	1.2	50
131	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3263-3272.	7.0	61
132	Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€generation sequencingâ€based leukemia prognostication panels. Cancer, 2018, 124, 2704-2713.	4.1	39
133	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Molecular Cancer Therapeutics, 2018, 17, 1595-1601.	4.1	30
134	Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 2018, 173, 355-370.e14.	28.9	620
135	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
136	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clinical Cancer Research, 2018, 24, 2719-2731.	7.0	54
137	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	6.4	7
138	Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. Journal of the National Cancer Institute, 2018, 110, 1409-1417.	6.3	53
139	Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell, 2018, 33, 450-462.e10.	16.8	213
140	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	7.0	127
141	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs, 2018, 36, 416-423.	2.6	17
142	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	2.6	90
143	Physician interpretation of genomic test results and treatment selection. Cancer, 2018, 124, 966-972.	4.1	10
144	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	7.0	225

#	Article	IF	CITATIONS
145	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. European Journal of Cancer, 2018, 89, 64-71.	2.8	3
146	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	9.4	243
147	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	2.6	149
148	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology, 2018, 2, 1-12.	3.0	86
149	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	1.6	1
150	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	2.1	5
151	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i> -Mutated Malignancies. JCO Precision Oncology, 2018, 2, 1-12.	3.0	13
152	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	1.6	79
153	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 2018, 36, 536-542.	1.6	362
154	Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	43
155	Molecular determinants of post-mastectomy breast cancer recurrence. Npj Breast Cancer, 2018, 4, 34.	5.2	9
156	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Journal of Cancer, 2018, 9, 3640-3646.	2.5	19
157	Signature program: a platform of basket trials. Oncotarget, 2018, 9, 21383-21395.	1.8	36
158	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research, 2018, 24, 6594-6610.	7.0	70
159	Challenges with biomarkers in cancer drug discovery and development. Expert Opinion on Drug Discovery, 2018, 13, 685-690.	5.0	28
160	Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Annals of Diagnostic Pathology, 2018, 35, 69-76.	1.3	16
161	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. Journal of Cutaneous Pathology, 2018, 45, 786-790.	1.3	18
162	Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE, 2018, 13, e0195932.	2.5	13

#	Article	IF	CITATIONS
163	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist, 2018, 23, 1300-1309.	3.7	46
164	Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion on Investigational Drugs, 2018, 27, 741-751.	4.1	43
165	Cancer driver mutation prediction through Bayesian integration of multi-omic data. PLoS ONE, 2018, 13, e0196939.	2.5	23
166	Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Cancer Research, 2018, 78, CT024-CT024.	0.9	6
167	Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma. Blood, 2018, 132, 1623-1623.	1.4	6
168	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L) Journal of Clinical Oncology, 2018, 36, 11514-11514.	1.6	30
169	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget, 2018, 9, 19891-19899.	1.8	28
170	Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270.	1.8	9
171	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget, 2018, 9, 33232-33243.	1.8	26
172	MK-2206 window of opportunity study in breast cancer. Annals of Translational Medicine, 2018, 6, S57-S57.	1.7	3
173	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	7.0	53
174	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clinical Cancer Research, 2017, 23, 1407-1413.	7.0	11
175	Targeting TRK family proteins in cancer. , 2017, 173, 58-66.		217
176	Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Investigational New Drugs, 2017, 35, 59-67.	2.6	10
177	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	2.5	27
178	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clinical Cancer Research, 2017, 23, 4020-4026.	7.0	14
179	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 509.	7.1	154
180	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clinical Cancer Research, 2017, 23, 5648-5656.	7.0	50

#	Article	IF	CITATIONS
181	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 4027-4034.	7.0	34
182	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research, 2017, 23, 6468-6477.	7.0	48
183	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. Journal of the National Cancer Institute, 2017, 109, .	6.3	16
184	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Research, 2017, 19, 93.	5.0	45
185	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963.	3.3	21
186	"Personalized Cancer Therapy― A Publicly Available Precision Oncology Resource. Cancer Research, 2017, 77, e123-e126.	0.9	31
187	Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Annals of Oncology, 2017, 28, iii145.	1.2	12
188	Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Annals of Surgical Oncology, 2017, 24, 652-659.	1.5	41
189	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
190	Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. JCO Precision Oncology, 2017, 1, 1-5.	3.0	3
191	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget, 2017, 8, 39254-39267.	1.8	62
192	Clinical Use of Precision Oncology Decision Support. JCO Precision Oncology, 2017, 2017, 1-12.	3.0	22
193	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	5.0	26
194	Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study Journal of Clinical Oncology, 2017, 35, 1017-1017.	1.6	2
195	Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of <i>WT p53</i> in patients with solid tumors and lymphomas Journal of Clinical Oncology, 2017, 35, 2505-2505.	1.6	71
196	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway Journal of Clinical Oncology, 2017, 35, 676-676.	1.6	30
197	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	2.5	65
198	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget, 2017, 8, 41806-41814.	1.8	12

#	Article	IF	CITATIONS
199	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	1.8	5
200	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	1.8	0
201	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience, 2016, 3, 164-172.	2.2	34
202	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. Oncotarget, 2016, 7, 54627-54631.	1.8	53
203	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	3.3	12
204	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	2.8	20
205	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189
206	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	7.0	38
207	Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 750-757.	4.4	23
208	Automated identification of molecular effects of drugs (AIMED). Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 758-765.	4.4	18
209	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology, 2016, 77, 973-977.	2.3	34
210	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.8	1
211	Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nature Genetics, 2016, 48, 1119-1130.	21.4	396
212	Biliary cancer: Utility of nextâ€generation sequencing for clinical management. Cancer, 2016, 122, 3838-3847.	4.1	289
213	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	9.4	192
214	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	5.5	106
215	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	4.1	78
216	Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology, 2016, 78, 167-171.	2.3	18

#	Article	IF	CITATIONS
217	Patient knowledge and information-seeking about personalized cancer therapy. International Journal of Medical Informatics, 2016, 88, 52-57.	3.3	19
218	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology, 2016, 27, 795-800.	1.2	150
219	Reply to M.P. Decatris et al. Journal of Clinical Oncology, 2016, 34, 886-886.	1.6	1
220	Clinical activity of ceritinib in <i>ROS1</i> -rearranged non-small cell lung cancer: Bench to bedside report. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1419-20.	7.1	29
221	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1699-1712.	7.0	95
222	A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Annals of Surgical Oncology, 2016, 23, 23-29.	1.5	5
223	Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight, 2016, 1, e90733.	5.0	19
224	<i>FGFR</i> pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy Journal of Clinical Oncology, 2016, 34, 109-109.	1.6	4
225	A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas Journal of Clinical Oncology, 2016, 34, 2581-2581.	1.6	20
226	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 3517-3517.	1.6	59
227	A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2016, 34, 3563-3563.	1.6	10
228	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC) Journal of Clinical Oncology, 2016, 34, 4568-4568.	1.6	26
229	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion Journal of Clinical Oncology, 2016, 34, 9069-9069.	1.6	10
230	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors Journal of Clinical Oncology, 2016, 34, 9073-9073.	1.6	5
231	Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors Journal of Clinical Oncology, 2016, 34, 653-653.	1.6	17
232	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget, 2016, 7, 64421-64430.	1.8	17
233	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	1.8	44
234	Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget, 2016, 7, 71686-71695.	1.8	7

#	Article	IF	CITATIONS
235	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016, 7, 76362-76373.	1.8	22
236	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	1.8	9
237	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. Cancer Drug Discovery and Development, 2016, , 151-180.	0.4	Ο
238	Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor Journal of Clinical Oncology, 2016, 34, 2546-2546.	1.6	0
239	Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies Journal of Clinical Oncology, 2016, 34, 2573-2573.	1.6	Ο
240	Clinical utilization of precision oncology decision support for genomically-informed cancer therapy Journal of Clinical Oncology, 2016, 34, 11605-11605.	1.6	0
241	Clinical next-generation sequencing in sarcomas Journal of Clinical Oncology, 2016, 34, 11046-11046.	1.6	0
242	ClinSeK: a targeted variant characterization framework for clinical sequencing. Genome Medicine, 2015, 7, 34.	8.2	13
243	Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav034-bav034.	3.0	9
244	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821.	1.8	86
245	Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget, 2015, 6, 19500-19513.	1.8	24
246	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015, 6, 12890-12908.	1.8	92
247	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	30
248	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 325-331.	2.4	18
249	Whole Genome Sequencing in Cancer Clinics. EBioMedicine, 2015, 2, 15-16.	6.1	4
250	RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 788-793.	3.6	65
251	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	3.2	85
252	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	7.0	70

#	Article	IF	CITATIONS
253	Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017. Annals of Surgical Oncology, 2015, 22, 75-81.	1.5	12
254	Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. Genome Medicine, 2015, 7, 6.	8.2	6
255	Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2015, 22, 431-441.	3.1	26
256	Attitudes toward molecular testing for personalized cancer therapy. Cancer, 2015, 121, 243-250.	4.1	45
257	Hepatocellular carcinoma: Where there is unmet need. Molecular Oncology, 2015, 9, 1501-1509.	4.6	64
258	The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discovery Today, 2015, 20, 1433-1438.	6.4	58
259	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	168
260	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer, 2015, 15, 153-160.	2.4	33
261	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 144, 713-721.	0.7	34
262	TransVar: a multilevel variant annotator for precision genomics. Nature Methods, 2015, 12, 1002-1003.	19.0	67
263	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2753-2762.	1.6	372
264	Genotype-Phenotype Correlations by Ethnicity and Mutation Location in <i>BRCA</i> Mutation Carriers. Breast Journal, 2015, 21, 260-267.	1.0	21
265	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
266	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clinical Genitourinary Cancer, 2015, 13, e19-e26.	1.9	18
267	The role of surgeons in building a personalized medicine program. Journal of Surgical Oncology, 2015, 111, 3-8.	1.7	5
268	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.7	138
269	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS ONE, 2015, 10, e0136851.	2.5	54
270	Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580.	2.2	42

#	Article	IF	CITATIONS
271	Functional consequence of the <i>MET-T</i> 1010I polymorphism in breast cancer. Oncotarget, 2015, 6, 2604-2614.	1.8	34
272	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	1.8	41
273	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	1.8	45
274	Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib. Blood, 2015, 126, 1386-1386.	1.4	0
275	Targeting translation initiation in breast cancer. Translation, 2014, 2, e28968.	2.9	1
276	Attitudes regarding privacy of genomic information in personalized cancer therapy. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e320-e325.	4.4	27
277	Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. Biomedical Optics Express, 2014, 5, 183.	2.9	16
278	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics, 2014, 13, 3175-3184.	4.1	31
279	Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Molecular Therapy, 2014, 22, 1310-1319.	8.2	62
280	Chemotherapy: Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site―and Sequence‧pecific Drug Release (Adv. Funct. Mater. 30/2014). Advanced Functional Materials, 2014, 24, 4868-4868.	14.9	0
281	Next-Generation Sequencing: How Close Are We to Clinical Application?. Breast Diseases, 2014, 25, 296-299.	0.0	0
282	Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research, 2014, 20, 6336-6345.	7.0	70
283	Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	7.0	529
284	Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics, 2014, 30, 1073-1080.	4.1	39
285	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical Breast Cancer, 2014, 14, 468-474.	2.4	29
286	Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 316-323.	2.5	18
287	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature, 2014, 512, 155-160.	27.8	911
288	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Journal of Hematology and Oncology, 2014, 7, 52.	17.0	33

#	Article	IF	CITATIONS
289	Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Annals of Diagnostic Pathology, 2014, 18, 266-270.	1.3	6
290	PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research, 2014, 2, 361-370.	3.4	994
291	Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients. Annals of Surgical Oncology, 2014, 21, 60-65.	1.5	38
292	Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site―and Sequence‧pecific Drug Release. Advanced Functional Materials, 2014, 24, 4753-4761.	14.9	36
293	Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. Cancer Cell, 2014, 26, 7-9.	16.8	8
294	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 1382-1389.	4.1	104
295	Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. Clinical Cancer Research, 2014, 20, 3870-3883.	7.0	47
296	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	12.8	456
297	Reply to Letter. Annals of Surgery, 2014, 259, e50.	4.2	0
298	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	2.5	50
299	Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE, 2014, 9, e115383.	2.5	362
300	<i>MET</i> aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget, 2014, 5, 1837-1845.	1.8	27
301	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	1.8	54
302	<i>BRAF</i> V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget, 2014, 5, 3607-3610.	1.8	63
303	Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget, 2014, 5, 9049-9064.	1.8	20
304	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget, 2014, 5, 8544-8557.	1.8	56
305	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget, 2014, 5, 9864-9876.	1.8	188
306	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discovery Medicine, 2014, 17, 101-14.	0.5	41

#	Article	IF	CITATIONS
307	Adapting a natural language processing tool to facilitate clinical trial curation for personalized cancer therapy. AMIA Summits on Translational Science Proceedings, 2014, 2014, 126-31.	0.4	8
308	Frequency of mesenchymalâ€epithelial transition factor gene (<i>MET</i>) and the catalytic subunit of phosphoinositideâ€3â€kinase (<i>PIK3CA</i>) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer, 2013, 119, 7-15.	4.1	49
309	Primary Tumor Extirpation in Breast Cancer Patients Who Present with Stage IV Disease is Associated with Improved Survival. Annals of Surgical Oncology, 2013, 20, 1893-1899.	1.5	67
310	Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted?. Annals of Surgical Oncology, 2013, 20, 4103-4112.	1.5	48
311	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncology. The. 2013. 14. 1317-1325.	10.7	148
312	Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience. Cancer Research, 2013, 73, 1449-1453.	0.9	75
313	Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. Surgical Oncology Clinics of North America, 2013, 22, 641-664.	1.5	161
314	Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy. Annals of Surgical Oncology, 2013, 20, 1514-1521.	1.5	21
315	Impact of the American College of Surgeons Oncology Group Z0011 Criteria Applied to a Contemporary Patient Population. Journal of the American College of Surgeons, 2013, 216, 105-113.	0.5	63
316	High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Research and Treatment, 2013, 137, 319-327.	2.5	90
317	The Impact of Tumor Heterogeneity on Patient Treatment Decisions. Clinical Chemistry, 2013, 59, 38-40.	3.2	10
318	Career track of Society of University Surgeons Resident Research Award recipients. Journal of Surgical Research, 2013, 185, 92-96.	1.6	11
319	Genotype in <i>BRCA</i> -associated Breast Cancers. Breast Journal, 2013, 19, 87-91.	1.0	6
320	Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Letters, 2013, 334, 245-252.	7.2	65
321	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Cancer, 2013, 119, 1776-1783.	4.1	166
322	Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857.	1.6	101
323	Two Birds With One Stone: Octreotide Treatment for Acromegaly and Breast Cancer. Journal of Clinical Oncology, 2013, 31, e398-e400.	1.6	6
324	Weekly <i>nab</i> -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clinical Cancer Research, 2013, 19, 5474-5484.	7.0	72

#	Article	IF	CITATIONS
325	Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?. Clinical Cancer Research, 2013, 19, 4305-4308.	7.0	8
326	Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist, 2013, 18, 1167-1173.	3.7	62
327	Locoregional Interaction of Ixabepilone (Ixempra) After Breast Cancer Radiation. Oncologist, 2013, 18, 265-270.	3.7	3
328	Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq. Journal of Virology, 2013, 87, 8916-8926.	3.4	187
329	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	7.0	597
330	Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy. Annals of Surgery, 2013, 257, 173-179.	4.2	83
331	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood, 2013, 122, 3048-3048.	1.4	1
332	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC) Journal of Clinical Oncology, 2013, 31, 5524-5524.	1.6	22
333	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS ONE, 2013, 8, e77945.	2.5	104
334	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience, 2013, 1, 5-13.	2.2	25
335	PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clinical Cancer Research, 2012, 18, 1777-1789.	7.0	191
336	Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. Clinical Cancer Research, 2012, 18, 5816-5828.	7.0	135
337	Reply to K.J. Van Zee et al. Journal of Clinical Oncology, 2012, 30, 3144-3145.	1.6	4
338	Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node. Annals of Surgery, 2012, 255, 109-115.	4.2	116
339	Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. Clinical Cancer Research, 2012, 18, 1109-1119.	7.0	62
340	cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes. Clinical Cancer Research, 2012, 18, 2269-2277.	7.0	108
341	Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Research, 2012, 14, R138.	5.0	62
342	American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Annals of Surgical Oncology, 2012, 19, 3144-3151.	1.5	157

#	Article	IF	CITATIONS
343	Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Annals of Surgical Oncology, 2012, 19, 3777-3784.	1.5	67
344	Overcoming implementation challenges of personalized cancer therapy. Nature Reviews Clinical Oncology, 2012, 9, 542-548.	27.6	115
345	Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2012, 19, 901-907.	1.5	47
346	Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline―and nonanthracyclineâ€based regimens for HER2â€positive breast cancer. Cancer, 2012, 118, 2385-2393.	4.1	54
347	Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer, 2012, 118, 4936-4943.	4.1	25
348	Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer, 2012, 118, 6287-6296.	4.1	33
349	Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Research and Treatment, 2012, 133, 1131-1141.	2.5	7
350	Prospective Evaluation of the Nipple–Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1137-1144.	1.5	116
351	Earlier age of onset of <i>BRCA</i> mutationâ€related cancers in subsequent generations. Cancer, 2012, 118, 321-325.	4.1	54
352	Predictive factors for <i>BRCA1</i> / <i>BRCA2</i> mutations in women with ductal carcinoma in situ. Cancer, 2012, 118, 1515-1522.	4.1	23
353	Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer, 2012, 118, 1498-1506.	4.1	69
354	Effect of metformin on survival outcomes in diabetic patients with triple receptorâ€negative breast cancer. Cancer, 2012, 118, 1202-1211.	4.1	144
355	Response to Neoadjuvant Systemic Therapy for Breast Cancer in <i>BRCA</i> Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal of Clinical Oncology, 2011, 29, 3739-3746.	1.6	151
356	Molecularâ€ŧargeted nanotherapies in cancer: Enabling treatment specificity. Molecular Oncology, 2011, 5, 492-503.	4.6	41
357	The Effect of Leucine Restriction on Akt/mTOR Signaling in Breast Cancer Cell Lines In Vitro and In Vivo. Nutrition and Cancer, 2011, 63, 264-271.	2.0	15
358	Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning. Annals of Surgery, 2011, 253, 572-579.	4.2	60
359	Delays in Primary Surgical Treatment Are Not Associated With Significant Tumor Size Progression in Breast Cancer Patients. Annals of Surgery, 2011, 254, 119-124.	4.2	37
360	Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Science, 2011, 102, 1247-1252.	3.9	216

#	Article	IF	CITATIONS
361	Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance. Breast Journal, 2011, 17, 210-212.	1.0	31
362	BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell, 2011, 20, 341-356.	16.8	67
363	Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clinical Breast Cancer, 2011, 11, 325-331.	2.4	62
364	Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Annals of Surgical Oncology, 2011, 18, 932-938.	1.5	42
365	Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Annals of Surgical Oncology, 2011, 18, 2407-2412.	1.5	113
366	Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology, 2011, 18, 3164-3173.	1.5	93
367	Reply: Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment. Annals of Surgical Oncology, 2011, 18, 288-289.	1.5	0
368	Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Research and Treatment, 2011, 130, 145-153.	2.5	96
369	Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer. Current Breast Cancer Reports, 2011, 3, 151-155.	1.0	6
370	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clinical Proteomics, 2011, 8, 11.	2.1	85
371	Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 2011, 117, 39-47.	4.1	59
372	Local, regional, and systemic recurrence rates in patients undergoing skinâ€sparing mastectomy compared with conventional mastectomy. Cancer, 2011, 117, 916-924.	4.1	87
373	A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer, 2011, 117, 2599-2607.	4.1	75
374	HER2 studies look promising. Cancer, 2011, 117, 1109-1109.	4.1	0
375	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. Clinical Cancer Research, 2011, 17, 6582-6591.	7.0	109
376	Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2628-2634.	1.6	128
377	Incidence and Outcome of <i>BRCA</i> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clinical Cancer Research, 2011, 17, 1082-1089.	7.0	487
378	Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2645-2652.	1.6	400

#	Article	IF	CITATIONS
379	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2011, 10, 1093-1101.	4.1	204
380	Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers. Journal of the National Cancer Institute, 2011, 103, 1871-1883.	6.3	104
381	Intra-Individual Comparison of Lymphatic Drainage Patterns Using Subareolar and Peritumoral Isotope Injection for Breast Cancer. Annals of Surgical Oncology, 2010, 17, 220-227.	1.5	3
382	Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Annals of Surgical Oncology, 2010, 17, 2899-2908.	1.5	74
383	Disseminated Tumor Cells in Biologic Subtypes of Stage l–III Breast Cancer Patients. Annals of Surgical Oncology, 2010, 17, 3252-3258.	1.5	14
384	Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer?. Annals of Surgical Oncology, 2010, 17, 280-285.	1.5	29
385	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clinical Proteomics, 2010, 6, 129-151.	2.1	203
386	Decreased TGFÎ ² signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment, 2010, 119, 305-314.	2.5	56
387	Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Research and Treatment, 2010, 123, 597-605.	2.5	8
388	Sentinel Lymph Node Dissection Is Technically Feasible in Older Breast Cancer Patients. Clinical Breast Cancer, 2010, 10, 477-482.	2.4	5
389	Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis. Clinical Breast Cancer, 2010, 10, S59-S65.	2.4	116
390	Histologic changes associated with falseâ€negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph nodeâ€positive breast cancer before treatment. Cancer, 2010, 116, 2878-2883.	4.1	49
391	A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer, 2010, 116, 2543-2548.	4.1	66
392	Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2â€positive breast cancer. Cancer, 2010, 116, 2884-2889.	4.1	194
393	Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. Cancer Prevention Research, 2010, 3, 1026-1034.	1.5	138
394	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1821-1828.	1.6	128
395	Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 2770-2784.	4.1	59
396	High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study. Biomedical Optics Express, 2010, 1, 911.	2.9	21

#	Article	IF	CITATIONS
397	Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncology, The, 2010, 11, 373-382.	10.7	114
398	Metformin: A Therapeutic Opportunity in Breast Cancer. Clinical Cancer Research, 2010, 16, 1695-1700.	7.0	184
399	RNA-binding specificity of Y-box protein 1. RNA Biology, 2009, 6, 59-64.	3.1	33
400	High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prevention Research, 2009, 2, 122-127.	1.5	33
401	High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller. Journal of Clinical Oncology, 2009, 27, 5700-5706.	1.6	404
402	Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Molecular Cancer Therapeutics, 2009, 8, 1157-1168.	4.1	83
403	Loss of <i>HER2</i> Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. Clinical Cancer Research, 2009, 15, 7381-7388.	7.0	281
404	Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. Journal of Clinical Oncology, 2009, 27, 220-226.	1.6	115
405	Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function. Cancer Cell, 2009, 15, 304-314.	16.8	175
406	Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer, 2009, 115, 962-971.	4.1	56
407	The impact of pregnancy on breast cancer outcomes in women â‰ 8 5 years. Cancer, 2009, 115, 1174-1184.	4.1	154
408	Perception of screening and risk reduction surgeries in patients tested for a <i>BRCA</i> deleterious mutation. Cancer, 2009, 115, 1598-1604.	4.1	31
409	Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Research and Treatment, 2009, 117, 61-68.	2.5	34
410	HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Research and Treatment, 2009, 113, 501-507.	2.5	73
411	False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden. Breast Journal, 2009, 15, 645-648.	1.0	12
412	Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. Annals of Surgical Oncology, 2009, 16, 1606-1611.	1.5	50
413	Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. American Journal of Surgery, 2009, 198, 720-725.	1.8	66
414	Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. American Journal of Surgery, 2009, 198, 387-391.	1.8	17

#	Article	IF	CITATIONS
415	The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Molecular Cancer, 2009, 8, 75.	19.2	26
416	Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3297-3302.	1.6	795
417	Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors, 2009, 27, 12-21.	1.7	34
418	Targeting the mTOR Signaling Network for Cancer Therapy. Journal of Clinical Oncology, 2009, 27, 2278-2287.	1.6	587
419	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. Annals of Surgery, 2009, 250, 558-566.	4.2	270
420	Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged â‰ \$ 5 years. Breast Cancer Research and Treatment, 2008, 110, 357-366.	2.5	24
421	Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer. Cancer, 2008, 112, 1206-1213.	4.1	92
422	Prognostic significance of HERâ€⊋ status in women with inflammatory breast cancer. Cancer, 2008, 112, 1905-1911.	4.1	54
423	Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer, 2008, 112, 2352-2358.	4.1	56
424	Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer, 2008, 112, 2646-2654.	4.1	38
425	How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer, 2008, 113, 30-37.	4.1	78
426	Translation Initiation Factor 4E (eIF4E): Prognostic Marker and Potential Therapeutic Target. Annals of Surgical Oncology, 2008, 15, 2996-2997.	1.5	7
427	Lymphovascular Invasion and Lobular Histology are Associated with Increased Incidence of Isolated Tumor Cells in Sentinel Lymph Nodes from Early-Stage Breast Cancer Patients. Annals of Surgical Oncology, 2008, 15, 3369-3377.	1.5	40
428	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer, 2008, 8, 101.	2.6	22
429	Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. American Journal of Surgery, 2008, 196, 81-87.	1.8	67
430	Intraoperative Margin Analysis in Breast-Conserving Surgery. Breast Diseases, 2008, 19, 25-26.	0.0	0
431	Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study. Journal of Clinical Oncology, 2008, 26, 4311-4318.	1.6	622
432	Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response. Oncologist, 2008, 13, 6-15.	3.7	23

#	Article	IF	CITATIONS
433	eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Molecular Cancer Therapeutics, 2008, 7, 1782-1788.	4.1	99
434	Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer, 2008, 15, 257-266.	3.1	137
435	Surgical Options for Breast Cancer. , 2008, , 197-234.		3
436	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal of Clinical Oncology, 2007, 25, 2650-2655.	1.6	253
437	Trends for Inflammatory Breast Cancer: Is Survival Improving?. Oncologist, 2007, 12, 904-912.	3.7	106
438	Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. American Journal of Surgery, 2007, 194, 527-531.	1.8	74
439	Rapamycin regulates the phosphorylation of rictor. Biochemical and Biophysical Research Communications, 2007, 362, 330-333.	2.1	55
440	Metastases to the breast from nonbreast solid neoplasms. Cancer, 2007, 110, 731-737.	4.1	151
441	Low locoregional failure rates in selected breast cancer patients with tumorâ€positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer, 2007, 110, 723-730.	4.1	145
442	Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer, 2007, 110, 2542-2550.	4.1	25
443	Eukaryotic Initiation Factor 4E (eIF4E) can be effectively downregulated using small interfering RNA (siRNA), inhibiting growth in breast cancer cells. Journal of the American College of Surgeons, 2007, 205, S92-S93.	0.5	0
444	Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery. Annals of Surgical Oncology, 2007, 14, 1458-1471.	1.5	229
445	Heterogenic Loss of BRCA in Breast Cancer: The "Two-Hit―Hypothesis Takes a Hit. Annals of Surgical Oncology, 2007, 14, 2428-2429.	1.5	16
446	Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases after a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2007, 14, 2422-2423.	1.5	10
447	Currency of online breast cancer information. Studies in Health Technology and Informatics, 2007, 129, 973-6.	0.3	2
448	Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women <=55 years. Carcinogenesis, 2006, 27, 2209-2216.	2.8	58
449	Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor. Annals of Surgical Oncology, 2006, 13, 776-782.	1.5	238
450	Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. American Journal of Surgery, 2006, 192, 541-544.	1.8	17

#	Article	IF	CITATIONS
451	Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. American Journal of Surgery, 2006, 192, 552-555.	1.8	61
452	Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy. Annals of Surgery, 2006, 243, 257-264.	4.2	217
453	Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. Annals of Surgery, 2006, 244, 464-470.	4.2	135
454	Incidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical Pathways. Annals of Surgery, 2006, 243, 96-101.	4.2	81
455	Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2006, 13, 310-320.	1.5	120
456	Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2006, 13, 1443-1449.	1.5	89
457	Use of Lymphoscintigraphy Defines Lymphatic Drainage Patterns Before Sentinel Lymph Node Biopsy for Breast Cancer. Journal of the American College of Surgeons, 2006, 203, 64-72.	0.5	37
458	Comparative Analysis of Sentinel Lymph Node Operation in Male and Female Breast Cancer Patients. Journal of the American College of Surgeons, 2006, 203, 475-480.	0.5	94
459	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 2006, 10, 145-157.	16.8	137
460	Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell, 2006, 10, 89-91.	16.8	55
461	Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer, 2006, 106, 42-50.	4.1	24
462	The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 2006, 107, 1248-1254.	4.1	44
463	Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer, 2006, 107, 1440-1447.	4.1	79
464	ls intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?. Cancer, 2006, 107, 2328-2336.	4.1	29
465	Association between clinical characteristics and riskâ€reduction interventions in women who underwent <i>BRCA1</i> and <i>BRCA2</i> testing. Cancer, 2006, 107, 2745-2751.	4.1	61
466	Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy: Fig. 1 Clinical Cancer Research, 2006, 12, 6326-6330.	7.0	114
467	Immediate Breast Reconstruction can Impact Postmastectomy Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 485-494.	1.3	88
468	Lymphatic Drainage Patterns on Early Versus Delayed Breast Lymphoscintigraphy Performed after Injection of Filtered Tc-99m Sulfur Colloid in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy. Clinical Nuclear Medicine, 2005, 30, 11-15.	1.3	40

#	Article	IF	CITATIONS
469	Instruments to assess the quality of health information on the World Wide Web: what can our patients actually use?. International Journal of Medical Informatics, 2005, 74, 13-19.	3.3	210
470	Searching for cancer-related information online: Unintended retrieval of complementary and alternative medicine information. International Journal of Medical Informatics, 2005, 74, 685-693.	3.3	14
471	Usability of quality measures for online health information: Can commonly used technical quality criteria be reliably assessed?. International Journal of Medical Informatics, 2005, 74, 675-683.	3.3	44
472	Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Journal of the American College of Surgeons, 2005, 200, 516-526.	0.5	272
473	Potential Role of Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy. Clinical Breast Cancer, 2005, 6, 357-360.	2.4	10
474	Breast conservation after neoadjuvant chemotherapy. Cancer, 2005, 103, 689-695.	4.1	130
475	Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer, 2005, 103, 1323-1329.	4.1	38
476	Improving local control with breast-conserving therapy. Cancer, 2005, 104, 20-29.	4.1	109
477	Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer, 2005, 104, 479-490.	4.1	46
478	Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis. Cancer, 2005, 104, 692-699.	4.1	92
479	Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity. Cancer Research, 2005, 65, 1961-1972.	0.9	98
480	Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. American Journal of Surgery, 2005, 190, 598-601.	1.8	12
481	Determinants of mastectomy in breast conservation therapy candidates. American Journal of Surgery, 2005, 190, 602-605.	1.8	13
482	Paget's Disease of the Breast: There Is a Role for Breast-Conserving Therapy. Annals of Surgical Oncology, 2005, 12, 391-397.	1.5	70
483	Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2004, 22, 2303-2312.	1.6	359
484	Anaphylactoid Reactions to Isosulfan Blue Dye During Breast Cancer Lymphatic Mapping in Patients Given Preoperative Prophylaxis. Journal of Clinical Oncology, 2004, 22, 567-568.	1.6	49
485	Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 1013-1023.	7.0	269
486	Molecular therapeutics: promise and challenges. Seminars in Oncology, 2004, 31, 39-53.	2.2	24

#	Article	IF	CITATIONS
487	Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy. Annals of Surgical Oncology, 2004, 11, 854-860.	1.5	62
488	Serum Proteomics for BRCA1-associated Breast Cancer. Annals of Surgical Oncology, 2004, 11, 883-884.	1.5	3
489	Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer, 2004, 100, 490-498.	4.1	34
490	Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer, 2004, 100, 942-949.	4.1	48
491	The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer, 2004, 101, 1514-1523.	4.1	134
492	Contralateral prophylactic mastectomy. Cancer, 2004, 101, 1977-1986.	4.1	102
493	Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 7031-7042.	7.0	303
494	Breast conservation in breast cancer: surgical and adjuvant considerations. Current Opinion in Obstetrics and Gynecology, 2004, 16, 31-36.	2.0	11
495	Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites. Journal of Medical Internet Research, 2004, 6, e21.	4.3	69
496	Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome. Annals of Surgical Oncology, 2003, 10, 628-634.	1.5	76
497	Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. American Journal of Surgery, 2003, 186, 371-377.	1.8	118
498	Translation initiation in cancer: a novel target for therapy. Molecular Cancer Therapeutics, 2002, 1, 971-9.	4.1	85